Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV-1 in adults

Document first published:
Page updated:
Topic:
Publication type:
,

NHS England will commission bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV-1 in adults in accordance with the criteria outlined in this policy.

Document

Clinical Commissioning Policy: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

Clinical Commissioning Policy: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

  • PDF
  • 160 KB

Document

Clinical Panel Report 1: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

Clinical Panel Report 1: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

  • PDF
  • 95 KB

Document

Clinical Panel Report 2: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

Clinical Panel Report 2: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

  • PDF
  • 96 KB

Document

Consultation Report: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

Consultation Report: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

  • PDF
  • 64 KB

Document

CPAG Summary Report: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

CPAG Summary Report: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

  • PDF
  • 61 KB

Document

Engagement Report: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

Engagement Report: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

  • PDF
  • 51 KB

Document

Evidence Review: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

Evidence Review: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

  • PDF
  • 586 KB